GE HealthCare (NASDAQ: GEHC) builds the MRI, CT and PET scanners hospitals run every day, and through its Pharmaceutical Diagnostics segment, many of the radioactive tracers that go with them. It’s now reportedly in advanced talks to pay roughly $1 billion for Sofie Biosciences, a US radiopharmacy network, to bring more of that supply chain in-house [1]. That description is accurate as far as it goes. And the gap between what a company appears to be and what it actually controls is where significant, unmapped value almost always hides.
Most companies never look there. Not because the opportunity isn’t real — but because finding it requires a specific kind of analysis, one that starts not with what a company is buying, but with what it and its target already run that neither has ever separated out and sold. That’s the work Limitless Solutions Consulting does. The findings are rarely obvious. They are almost always actionable. What follows is what that lens turned up on GE HealthCare.
■ THE WRONG LENS
Every account of the Sofie talks reads the same way: GE HealthCare shoring up its supply chain for short-half-life isotopes, converting a vendor relationship into an owned asset, boosting the recurring-revenue side of a business that otherwise depends on lumpy hospital capital budgets. All reasonable. All measuring a supply-chain transaction.
Here’s what gets skimmed past. GE HealthCare’s Pharmaceutical Diagnostics segment already runs seven current-GMP manufacturing sites supporting more than 130 million imaging procedures a year across 100-plus countries [2], and fully owns Nihon Medi-Physics, a 13-facility Japanese radiopharmaceutical network it took full control of in December 2024 [3]. Sofie, the reported target, runs 17 US radiopharmacies of its own, most built to a dual-cyclotron, dual-hot-cell standard, serving roughly 400,000 patients a year across some 700 clinics [4]. Combined, that’s dozens of sites worldwide handling material that is, by definition, radioactive and clinically time-critical — every one operating under continuous radiation-safety and GMP compliance obligations. Every account of the deal describes that compliance discipline as a cost of running the business. None describes it as something a third party would pay to access.
■ WHAT GE HEALTHCARE ACTUALLY HAS
Before mapping where this goes, it’s worth listing what the combined company would run — not the deal terms, but the capabilities underneath them.
A global radiotracer manufacturing footprint. Seven GMP sites plus Nihon Medi-Physics’ 13 Japanese facilities, supporting 130 million-plus procedures annually [2][3].
A multi-jurisdiction regulatory clearance stack. FDA approval for products including Flyrcado, an in-licensed Phase II FAPI portfolio, and Japan’s regulatory pathway through Nihon Medi-Physics [3][6] — clearances that took years to assemble and lower the cost of launching any adjacent regulated product relative to a new entrant.
A short-half-life production and distribution discipline. Sofie’s own network already handles isotopes that must be produced, dispensed and delivered within hours, at 17 sites and counting, with a track record of expanding capacity — including a recent 20-fold increase in actinium-225 production — without disrupting existing service [5].
A proven willingness to license infrastructure outward. GE HealthCare’s 2023 licensing deal with Sofie for FAP-targeting radiotracers shows the company already using a partner’s regulatory and production footprint as its fast path to market [6] — the same mechanic run in reverse is the adjacency this piece tests.
■ THE ADJACENT MARKETS GE HEALTHCARE ISN’T FULLY IN (BUT COULD BE)
1. A compliance and safety-monitoring managed service for smaller radiopharma producers. The strongest of the two tested, scoring 18/25 — Viable but conditional. GE and Sofie’s combined network already runs radiation-safety and GMP compliance at dozens of sites without incident at scale — a discipline built over years, not a single certification. As more isotopes move from diagnostic to therapeutic use, more producers will be building or retrofitting sites that need exactly this discipline and don’t have it in-house. What caps it below Strong: no existing sales relationship with that buyer class exists today — this would be a new channel built from a standing start, even though the underlying capability is fully confirmed.
2. A regulatory-clearance licensing program for smaller radiopharma and theranostics developers. Scoring 17/25 — Viable but conditional. The mechanic: a smaller device or radiotracer developer without FDA or international clearance pays GE HealthCare a licensing or royalty fee to use its already-cleared pathway as importer of record or certified partner, instead of building that regulatory-affairs capability from scratch — the same mechanic identified inside Savaria’s dealer and clearance infrastructure in Issue #37. What keeps it Viable rather than Strong: it’s a structurally close repeat of an adjacency this newsletter has already surfaced elsewhere, which is a real overlap worth naming rather than a fresh blind spot.
■ WHAT WE RULED OUT
Two other candidates were tested and didn’t survive scrutiny. A drone or autonomous cold-chain delivery model for short-half-life isotopes has real logic — the time and temperature constraints are genuine — but scored 13/25 and was killed: neither GE HealthCare nor Sofie has any existing aviation, robotics or airspace-regulatory capability, so this would be built from zero rather than transferred, against an FAA/NRC dual-regulatory barrier that no operator in this category has cleared at scale. A contract-manufacturing or tolling play out of the combined cyclotron network was tested and excluded for a different reason: Sofie’s own materials already describe “mature contract manufacturing services” as a current offering [4] — this isn’t an unmonetized capability, it’s a fact GE HealthCare’s own target already states about itself, and including it here would mean reporting an existing line of business rather than surfacing a genuine blind spot.
■ THE REFRAME
Every account of a possible GE HealthCare–Sofie deal reads it as a supply-chain transaction: buy the isotopes instead of sourcing them. That’s a fair read of the reported terms. It’s an incomplete read of the assets. A company that would run dozens of radiation-regulated, continuously-audited sites across two continents isn’t just securing supply — it’s sitting on a compliance and clearance infrastructure that took years to build and has never been separated from the product it currently supports. This is the Contraction Trap at the company level — a capability earning real safety and regulatory value, treated as infrastructure, never extracted and priced. Filed under operations, not products.
■ THE SELF-TEST
1. What compliance or safety discipline does your business run every day that a customer would pay to access on its own?
2. What regulatory clearance did you build once that a smaller competitor would pay to use instead of rebuilding it?
3. What is currently filed under “cost of doing business safely” that could be filed under “product”?
■ CLOSING INSIGHT + CTA
None of this is a claim about GE HealthCare’s intentions, or confirmation that the Sofie deal will close — as of this writing it remains a reported, unconfirmed transaction, and neither company has commented on the record [1]. What’s described here is an analytical inference drawn from each company’s own confirmed disclosures, not a description of stated strategy.
I built a diagnostic that surfaces these questions for your own business. Run it here: limitlesssolutionsconsulting.com/amos/
This pattern of using existing capabilities to enter adjacent markets shows up across mid-market and enterprise companies alike — see the broader framework in Adjacent Market Opportunities: How Mid-Market Companies Find Revenue They’re Already Positioned to Own.
Warren Wurzer, CEO | Limitless Solutions Consulting
@warrenwurzer | limitlesssolutionsconsulting.com
■ REFERENCES
[1] “GE HealthCare in talks over possible $1 billion deal for Sofie Biosciences, FT reports,” Reuters, September 13, 2026. https://kelo.com/2026/09/13/ge-healthcare-in-talks-over-possible-1-billion-deal-for-sofie-biosciences-ft-reports/
[2] “Pharmaceutical Diagnostics,” GE HealthCare RSNA Press Kit, gehealthcare.com. https://www.gehealthcare.com/en/events/rsna-press-kit/pharmaceutical-diagnostics
[3] “GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP),” GE HealthCare newsroom, December 2024. https://www.gehealthcare.com/en/about/newsroom/press-releases/ge-healthcare-to-acquire-remaining-50-stake-in-nihon-medi-physics-nmp-a-leading-radiopharmaceutical-company-in-japan-from-sumitomo-chemical
[4] “Network,” SOFIE Biosciences, sofie.com. https://sofie.com/network/
[5] “Sofie Biosciences Acquires Texas Radiopharmacy,” AuntMinnie. https://www.auntminnie.com/clinical-news/molecular-imaging/nuclear-medicine/article/15623475/sofie-biosciences-acquires-texas-radiopharmacy
[6] “SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers,” Businesswire, October 9, 2023. https://www.businesswire.com/news/home/20231009674148/en